TODD ROSENGART to Endothelial Growth Factors
This is a "connection" page, showing publications TODD ROSENGART has written about Endothelial Growth Factors.
Connection Strength
1.614
-
Gene therapy with adenovirus-mediated myocardial transfer of vascular endothelial growth factor 121 improves cardiac performance in a pacing model of congestive heart failure. J Thorac Cardiovasc Surg. 2002 Jun; 123(6):1101-13.
Score: 0.184
-
Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann Thorac Surg. 2000 Jan; 69(1):14-23; discussion 23-4.
Score: 0.156
-
Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg. 1999 Oct; 230(4):466-70; discussion 470-2.
Score: 0.153
-
Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation. 1999 Aug 03; 100(5):468-74.
Score: 0.152
-
The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling. J Biol Chem. 1999 Apr 09; 274(15):10002-7.
Score: 0.148
-
Therapeutic angiogenesis: protein and gene therapy delivery strategies. J Cardiovasc Risk. 1999 Feb; 6(1):29-40.
Score: 0.146
-
Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. J Vasc Surg. 1998 Apr; 27(4):699-709.
Score: 0.138
-
Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg. 1998 Jan; 115(1):168-76; discussion 176-7.
Score: 0.136
-
Vascular endothelial growth factor is the major angiogenic factor in omentum: mechanism of the omentum-mediated angiogenesis. J Surg Res. 1997 Feb 01; 67(2):147-54.
Score: 0.127
-
Gene therapy for coronary artery disease. Adv Card Surg. 2001; 13:107-20.
Score: 0.042
-
Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary. Circulation. 2000 Sep 12; 102(11):E73-86.
Score: 0.041
-
Safety of direct myocardial administration of an adenovirus vector encoding vascular endothelial growth factor 121. Hum Gene Ther. 1999 May 20; 10(8):1331-48.
Score: 0.037
-
Transmyocardial laser revascularization and angiogenesis: the potential for therapeutic benefit. Semin Thorac Cardiovasc Surg. 1999 Jan; 11(1):29-35.
Score: 0.036
-
Regional angiogenesis induced in nonischemic tissue by an adenoviral vector expressing vascular endothelial growth factor. Hum Gene Ther. 1997 Jan 20; 8(2):215-27.
Score: 0.032
-
Direct in vivo gene transfer to canine myocardium using a replication-deficient adenovirus vector. Ann Thorac Surg. 1996 Aug; 62(2):425-33; discussion 433-4.
Score: 0.031
-
Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes. Mol Ther. 2002 Aug; 6(2):287-97.
Score: 0.012
-
Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther. 2002 Jan 01; 13(1):15-63.
Score: 0.011
-
Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum Gene Ther. 2002 Jan 01; 13(1):65-100.
Score: 0.011
-
Use of quantitative TaqMan real-time PCR to track the time-dependent distribution of gene transfer vectors in vivo. Mol Ther. 2000 Dec; 2(6):649-56.
Score: 0.010
-
Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J Virol. 1999 Aug; 73(8):6729-42.
Score: 0.009